de Almeida_2023_Pharmaceuticals.(Basel)_16_

Reference

Title : Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies - de Almeida_2023_Pharmaceuticals.(Basel)_16_
Author(s) : de Almeida RBM , Barbosa DB , do Bomfim MR , Amparo JAO , Andrade BS , Costa SL , Campos JM , Cruz JN , Santos CBR , Leite FHA , Botura MB
Ref : Pharmaceuticals (Basel) , 16 : , 2023
Abstract :

The enhancement of cholinergic functions via acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition is considered a valuable therapeutic strategy for the treatment of Alzheimer's disease. This study aimed to evaluate the in vitro effect of ZINC390718, previously filtered using computational approaches, on both cholinesterases and to characterize, using a molecular dynamics (MD) simulation, the possible binding mode of this compound inside the cholinesterase enzymes. The in vitro cytotoxicity effect was also investigated using a primary astrocyte-enriched glial cell culture. ZINC390718 presented in vitro dual inhibitory activity against AChE at a high micromolar range (IC(50) = 543.8 microM) and against BuChE (IC(50) = 241.1 microM) in a concentration-dependent manner, with greater activity against BuChE. The MD simulation revealed that ZINC390718 performed important hydrophobic and H-bond interactions with the catalytic residue sites on both targets. The residues that promoted the hydrophobic interactions and H-bonding in the AChE target were Leu67, Trp86, Phe123, Tyr124, Ser293, Phe295, and Tyr341, and on the BuChE target, they were Asp70, Tyr332, Tyr128, Ile442, Trp82, and Glu197. The cytotoxic effect of Z390718, evaluated via cell viability, showed that the molecule has low in vitro toxicity. The in vitro and in silico results indicate that ZINC390718 can be used as chemotype for the optimization and identification of new dual cholinesterase inhibitors.

PubMedSearch : de Almeida_2023_Pharmaceuticals.(Basel)_16_
PubMedID: 36678592

Related information

Citations formats

de Almeida RBM, Barbosa DB, do Bomfim MR, Amparo JAO, Andrade BS, Costa SL, Campos JM, Cruz JN, Santos CBR, Leite FHA, Botura MB (2023)
Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies
Pharmaceuticals (Basel) 16 :

de Almeida RBM, Barbosa DB, do Bomfim MR, Amparo JAO, Andrade BS, Costa SL, Campos JM, Cruz JN, Santos CBR, Leite FHA, Botura MB (2023)
Pharmaceuticals (Basel) 16 :